cjc 1295 ipamorelin with tirzepatide Buy CJC-1295+Ipamorelin Blend CJC-1295 No DAC + Ipamorelin

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

Gastrointestinal events, such as nausea, diarrhea, vomiting, and constipation, were the most frequently reported adverse effects compared to the placebo

Head-to-head trials show tirzepatide producing 3-5 percentage points greater weight loss at comparable timepoints

doi: 10.1111/ijpo.12837

I laughed, confessing my current kiwi addiction after discovering some particularly sweet ones my mum had bought last week